iStock/Sundry Photography
Abbott announced today it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the companies in cases related to continuous glucose monitoring products.
The agreement will result in the dismissal of all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years. There are no financial payments associated with the settlement from either Abbott or Dexcom.
Abbott considers this agreement a positive development, as it allows the company to fully focus on supporting people with diabetes with its technologies and services.
Details of the settlement are confidential.
